1. Continuous glucose monitoring in patients with type 2 diabetes treated with glucagon‐like peptide‐1 receptor agonist dulaglutide in combination with prandial insulin lispro: an AWARD‐4 substudy. Issue 10 (22nd July 2016) Authors: Jendle, Johan; Testa, Marcia A.; Martin, Sherry; Jiang, Honghua; Milicevic, Zvonko Journal: Diabetes, obesity & metabolism Issue: Volume 18:Issue 10(2016) Page Start: 999 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Dulaglutide as add-on therapy to SGLT2 inhibitors in patients with inadequately controlled type 2 diabetes (AWARD-10): a 24-week, randomised, double-blind, placebo-controlled trial. Issue 5 (May 2018) Authors: Ludvik, Bernhard; Frías, Juan P; Tinahones, Francisco J; Wainstein, Julio; Jiang, Honghua; Robertson, Kenneth E; García-Pérez, Luis-Emilio; Woodward, D Bradley; Milicevic, Zvonko Journal: Lancet Issue: Volume 6:Issue 5(2018) Page Start: 370 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Dulaglutide treatment results in effective glycaemic control in latent autoimmune diabetes in adults (LADA): A post‐hoc analysis of the AWARD‐2, ‐4 and ‐5 Trials. Issue 6 (21st February 2018) Authors: Pozzilli, Paolo; Leslie, Richard D.; Peters, Anne L.; Buzzetti, Raffaella; Shankar, Sudha S.; Milicevic, Zvonko; Pavo, Imre; Lebrec, Jeremie; Martin, Sherry; Schloot, Nanette C. Journal: Diabetes, obesity & metabolism Issue: Volume 20:Issue 6(2018) Page Start: 1490 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. Effect of once‐weekly dulaglutide versus insulin glargine in people with type 2 diabetes and different baseline glycaemic patterns: A post hoc analysis of the AWARD‐2 clinical trial. Issue 11 (16th August 2019) Authors: Giorgino, Francesco; Yu, Maria; Haupt, Axel; Milicevic, Zvonko; García‐Pérez, Luis‐Emilio Journal: Diabetes, obesity & metabolism Issue: Volume 21:Issue 11(2019) Page Start: 2570 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. Effects of subcutaneous tirzepatide versus placebo or semaglutide on pancreatic islet function and insulin sensitivity in adults with type 2 diabetes: a multicentre, randomised, double-blind, parallel-arm, phase 1 clinical trial. Issue 6 (June 2022) Authors: Heise, Tim; Mari, Andrea; DeVries, J Hans; Urva, Shweta; Li, Jing; Pratt, Edward John; Coskun, Tamer; Thomas, Melissa K; Mather, Kieren J; Haupt, Axel; Milicevic, Zvonko Journal: Lancet Issue: Volume 10:Issue 6(2022) Page Start: 418 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. Efficacy and safety of an expanded dulaglutide dose range: A phase 2, placebo‐controlled trial in patients with type 2 diabetes using metformin. Issue 9 (3rd June 2019) Authors: Frias, Juan P.; Wynne, Alan G.; Matyjaszek‐Matuszek, Beata; Bartaskova, Dagmar; Cox, David A.; Woodward, Brad; Li, Ying G.; Tham, Lai S.; Milicevic, Zvonko Journal: Diabetes, obesity & metabolism Issue: Volume 21:Issue 9(2019) Page Start: 2048 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial. Issue 10160 (17th November 2018) Authors: Frias, Juan Pablo; Nauck, Michael A; Van, Joanna; Kutner, Mark E; Cui, Xuewei; Benson, Charles; Urva, Shweta; Gimeno, Ruth E; Milicevic, Zvonko; Robins, Deborah; Haupt, Axel Journal: Lancet Issue: Volume 392:Issue 10160(2018) Page Start: 2180 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. Efficacy and tolerability of tirzepatide, a dual glucose‐dependent insulinotropic peptide and glucagon‐like peptide‐1 receptor agonist in patients with type 2 diabetes: A 12‐week, randomized, double‐blind, placebo‐controlled study to evaluate different dose‐escalation regimens. Issue 6 (11th February 2020) Authors: Frias, Juan Pablo; Nauck, Michael A.; Van, Joanna; Benson, Charles; Bray, Ross; Cui, Xuewei; Milicevic, Zvonko; Urva, Shweta; Haupt, Axel; Robins, Deborah A. Journal: Diabetes, obesity & metabolism Issue: Volume 22:Issue 6(2020) Page Start: 938 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. LY3437943, a novel triple GIP, GLP-1, and glucagon receptor agonist in people with type 2 diabetes: a phase 1b, multicentre, double-blind, placebo-controlled, randomised, multiple-ascending dose trial. Issue 10366 (26th November 2022) Authors: Urva, Shweta; Coskun, Tamer; Loh, Mei Teng; Du, Yu; Thomas, Melissa K; Gurbuz, Sirel; Haupt, Axel; Benson, Charles T; Hernandez-Illas, Martha; D'Alessio, David A; Milicevic, Zvonko Journal: Lancet Issue: Volume 400:Issue 10366(2022) Page Start: 1869 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
10. Once-weekly dulaglutide versus bedtime insulin glargine, both in combination with prandial insulin lispro, in patients with type 2 diabetes (AWARD-4): a randomised, open-label, phase 3, non-inferiority study. Issue 9982 (23rd May 2015) Authors: Blonde, Lawrence; Jendle, Johan; Gross, Jorge; Woo, Vincent; Jiang, Honghua; Fahrbach, Jessie L; Milicevic, Zvonko Journal: Lancet Issue: Volume 385:Issue 9982(2015) Page Start: 2057 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗